Dependence of correlations between antibody titres and opsonophagocytosis on pneumococcal serotype and patient morbidity in pre- and post-pneumococcal vaccination states

Clinical Microbiology and Infection

Volumn 13, Issue 4, 2007, Pages 369-376

  Tarragó, Dav ^a   Aguilar, L ^b   Jansen, W T M ^c   Gimenez M J ^b   Avellon A ^a   Granizo, J J ^d   Casal, J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Haemodialysis; IgG; Immune response; Opsonophagocytosis; Pneumococcal polysaccharide vaccine; Streptococcus pneumoniae

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; OPSONIN; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; RECIPIENT; SEROTYPE; SPAIN; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

STREPTOCOCCUS PNEUMONIAE;

EID: 33847788187     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01677.x     Document Type: Article

References (30)

1. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332: 1280-1284.
2. Hu BT, Yu X, Jones TR et.al. Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin Diagn Lab Immunol 2005; 12: 287-295.
3. Plikaytis BD, Goldblatt D, Frasch CE et.al. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol 2000; 38: 2043-2050.
4. Anttila M, Voutilainen M, Jantti V, Eskola J, Kayhty H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol 1999; 118: 402-407.
5. Johnson SE, Rubin L, Romero-Steiner S et.al. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis 1999; 180: 133-140.
6. Saeland E, Jakobsen H, Ingolfsdottir G, Sigurdardottir ST, Jonsdottir I. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J Infect Dis 2001; 183: 253-260.
7. Romero-Steiner S, Libutti D, Pais LB et.al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4: 415-422.
8. Jodar L, Butler J, Carlone G et.al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21: 3265-3272.
9. TarragóD, Casal J, Ruiz-Contreras J et.al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005; 12: 165-170.
10. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165 (suppl 1): S49-S52.
11. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187: 1639-1645.
12. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46 (RR-8): 1-24.
13. Pérez-Trallero E, García-de-la-Fuente C, García-Rey C et.al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-1972.
14. Fenoll A, Asensio G, Jado I et.al. Antimicrobial susceptibility and pneumococcal serotypes. J Antimicrob Chemother 2002; 50 (suppl S2): 13-19.
15. Marco F, Bouza E, García-de-Lomas J, Aguilar L, Spanish Surveillance Group for Respiratory Pathogens. Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: The impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics. J Antimicrob Chemother 2000; 46: 557-564.
16. Soininen A, Karpala M, Wahlman SL, Lehtonen H, Kayhty H. Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children. Clin Diagn Lab Immunol 2002; 9: 1032-1038.
17. Concepción NF, Frasch CE. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin Diagn Lab Immunol 1998; 5: 199-204.
18. Quataert SA, Kirch CS, Wiedl LJ et.al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995; 2: 590-597.
19. Fenoll A, Jado I, Vicioso D, Pérez A, Casal J. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990-1996). J Clin Microbiol 1998; 36: 3447-3454.
20. Jansen WTM, Gootjes J, Zelle M et.al. Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin Diagn Lab Immunol 1998; 5: 703-710.
21. Nielsen SV, Sorensen UBS, Henrichsen J. Antibodies against pneumococcal C-polysaccharide are not protective. Microb Pathog 1993; 14: 299-305.
22. Jansen WTM, Breukels A, Snippe H, Sanders LA, Verheul AFM, Rijkers GT. Fcgamma receptor polymorphisms determine the magnitude of in vitro phagocytosis of Streptococcus pneumoniae mediated by pneumococcal conjugate sera. J Infect Dis 1999; 180: 888-891.
23. Shapiro ED, Berg AT, Austrian R et.al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-1460.
24. Coughlin RT, White AC, Anderson CA, Carlone GM, Klein DL, Treanor J. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine 1998; 16: 1761-1767.
25. Yu X, Sun Y, Frasch C, Concepción N, Nahm MH. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol 1999; 6: 519-524.
26. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus infected persons. incidence, risk factors, and impact of vaccination. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis 2001; 32: 794-800.
27. Chang Q, Alpert P, Abadi J, Pirofski L. A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from HIV-uninfected, but not HIV-infected individuals. J Infect Dis 2000; 181: 1313-1321.
28. Vakevainen M, Jansen W, Saeland E et.al. Are the opsonophagocytic activities of antibodies measured from infant sera by different pneumococcal phagocytic assays comparable? Clin Diagn Lab Immunol 2001; 8: 363-369.
29. Feikin DR, Elie CM, Goetz MB et.al. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. Clin Diagn Lab Immunol 2004; 11: 137-141.
30. Balmer P, North J, Baxter D et.al. Measurement and interpretation of pneumococcal IgG levels for clinical management. Clin Exp Immunol 2003; 133: 364-369.